This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Identification of High-Risk Coronary Heart Disease Patients Receiving Atypical Antipsychotics: Single Low-Density Lipoprotein Cholesterol Threshold or Complex National Standard?

Christoph U. Correll, MD; John M. Kane, MD; and Peter Manu, MD

Published: March 18, 2008

Article Abstract

Objective: Although psychiatric patients have a shortened life expectancy due to increased coronary heart disease (CHD), early identification of high-risk patients and targeted prevention for reduction of low-density lipoprotein (LDL) cholesterol are suboptimal in clinical care. We aimed to compare the accuracy of a single LDL-cholesterol intervention threshold of > 130 mg/dL (recently proposed for psychiatric patients) with that of the more complex LDL-cholesterol targets defined by the National Cholesterol Education Panel (NCEP). The study was performed in patients receiving second-generation antipsychotics (SGAs), a medication class associated with CHD risk.

Method: Three hundred fifty-six psychiatric patients receiving SGAs underwent standard LDL-cholesterol target assessments upon admission to the hospital between August 1, 2004, and March 1, 2005. The expert consensus-recommended > 130-mg/dL LDL-cholesterol threshold was used to determine false-negative results among patients with above-target NCEP-defined LDL cholesterol and false-positive results in the group with below-target NCEP-defined LDL cholesterol.

Results: The > 130-mg/dL threshold misclassified 15 (14.9%) of 101 high-risk patients and 31 (12.2%) of 255 low-risk patients (mean ± SD 10-year CHD risk: 23.1% ± 12.2% and 2.1% ±2.2%, respectively). Results were similar in the 171 schizophrenia patients. Misclassified patients with above-target LDL cholesterol were more likely than correctly identified patients to have diabetes (p = .0002), greater 10-year CHD risk (p = .0006), higher age (p = .0008), metabolic syndrome (p = .0018), and past CHD events (p = .0025). No distinguishing factors for false-positive cases could be identified.

Conclusions: The > 130-mg/dL LDL-cholesterol intervention threshold operated poorly in our psychiatric population. To avoid substandard care, NCEP-defined LDL-cholesterol targets should be used for the routine detection of psychiatric patients treated with antipsychotics who require interventions to decrease CHD risk.

Volume: 69

Quick Links: Neurologic and Neurocognitive , Neurology

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF